· Published by Health Canada · Official notice
| Lot | Expiry date | DIN | Product |
|---|---|---|---|
| JKX1910A JKX4318A JKX5541A HAC2371A HAC4421A HAD0156A | April-2023 Aug-2023 Nov-2023 Jun-2024 Nov-2024 Jan-2025 | 02415100 | Taro Zoledronic acid injection 5mg/100mL |
Taro Pharmaceuticals Inc. is recalling all lots of Taro-Zoledronic acid injection 5mg/100mL (DIN 02415100) because they may contain particulate matter.
Zoledronic acid is a prescription drug used to treat and prevent osteoporosis and to treat Paget's disease (a condition that disrupts the normal cycle of bone renewal).
If particulate matter is injected into a patient, there is potential for injury, such as inflammation or irritation of the veins, infections at the site of injection or in other parts of the body, allergic reactions, and the formation of blood clots that can move to other parts of the body. In the most serious cases, blood clots could move to the lungs and cause lung damage (pulmonary embolism), which can be permanent or fatal. Patients who have been treated with a recalled drug should go to the hospital immediately if they develop difficulty breathing, chest pain or confusion.
The Department is monitoring the company's recall and will inform the public if any new health risks are identified.